

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with *EGFR* mutation-positive non-small-cell lung cancer

Noboru Yamamoto¹ · Koichi Goto² · Makoto Nishio³ · Kenichi Chikamori⁴ ·
Toyoaki Hida⁵ · Makoto Maemondo⁶ · Nobuyuki Katakami⁷ · Toshiyuki Kozuki⁸ ·
Hiroshige Yoshioka⁹ · Takashi Seto¹⁰ · Kosei Tajima¹¹ · Tomohide Tamura¹²

Published online: 17 October 2016
© Japan Society of Clinical Oncology 2016

Erratum to: Int J Clin Oncol DOI 10.1007/s10147-016-1039-0

In the original publication of the article, Table 4 was published incorrectly. The corrected Table 4 is published with this erratum.

Table 4 Treatment-related adverse events, all grades ($\geq 30\%$) and grade ≥ 3

	All grades ($\geq 30\%$)	Grade ≥ 3
Rash	85 (82.5)	15 (14.6)
Diarrhea	82 (79.6)	1 (1.0)
Dry skin	82 (79.6)	5 (4.9)
Paronychia	69 (67.0)	1 (1.0)
Stomatitis	65 (63.1)	1 (1.0)
Pruritus	67 (65.0)	3 (2.9)
Decreased appetite	35 (34.0)	2 (1.9)
ALT increased	33 (32.0)	9 (8.7)

ALT alanine aminotransferase

The online version of the original article can be found under doi:[10.1007/s10147-016-1039-0](https://doi.org/10.1007/s10147-016-1039-0).

✉ Noboru Yamamoto
nbryamam@ncc.go.jp

- 1 Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan
- 2 Department of Thoracic Oncology, National Cancer Centre Hospital East, Kashiwa, Chiba, Japan
- 3 Thoracic Oncology Centre, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
- 4 Oncology Medicine, National Hospital Organization, Yamaguchi-Ube Medical Centre, Ube, Yamaguchi, Japan
- 5 Department of Thoracic Oncology, Aichi Cancer Centre Hospital, Nagoya, Aichi, Japan
- 6 Department of Respiratory Medicine, Miyagi Cancer Centre, Natori, Miyagi, Japan

- 7 Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe, Hyogo, Japan
- 8 Department of Thoracic Oncology, National Hospital Organization, Shikoku Cancer Centre, Matsuyama, Ehime, Japan
- 9 Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
- 10 Department of Thoracic Oncology, National Kyushu Cancer Centre, Fukuoka, Fukuoka, Japan
- 11 Clinical Research Planning Department, Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan
- 12 Thoracic Center, St Luke's International Hospital, Chuo-ku, Tokyo, Japan